Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1313-1327

  Harding, Brian ^a   Lemos, Manuel C ^a   Reed, Anita A C ^a   Walls, Gerard V ^a   Jeyabalan, Jeshmi ^a   Bowl, Michael R ^a   Tateossian, Hilda ^b   Sullivan, Nicky ^c   Hough, Tertius ^b   Fraser, William D ^d   Ansorge, Olaf ^c   Cheeseman, Michael T ^b   Thakker, Rajesh V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MRC MAMMALIAN GENETICS UNIT   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ALBUMIN; CALCIUM; CHROMOGRANIN A; CREATININE; METHIONINE; PARATHYROID HORMONE; PHOSPHATE; SOMATOSTATIN RECEPTOR 2; VASCULOTROPIN A;

ADRENAL CORTEX TUMOR; ADRENAL TUMOR; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CARCINOGENESIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOCRINE DISEASE; EXON; FEMALE; GENE DELETION; HETEROZYGOSITY LOSS; HYPERCALCEMIA; HYPERCORTICOSTERONEMIA; HYPOPHOSPHATEMIA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULINOMA; KNOCKOUT MOUSE; MALE; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PANCREAS TUMOR; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID TUMOR; PHOSPHATE BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADRENAL GLAND NEOPLASMS; ANIMALS; BLOTTING, WESTERN; CORTICOSTERONE; FEMALE; HYPERCALCEMIA; HYPOPHOSPHATEMIA; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS; PARATHYROID NEOPLASMS; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 72549106938     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0082     Document Type: Article

References (41)

1. Benson L, Ljunghall S, Akerstrom G & Oberg K 1987 Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. American Journal of Medicine 82 731-737. (Pubitemid 18138562)
2. Bertolino P, Tong WM, Galendo D, Wang ZQ & Zhang CX 2003a Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Molecular Endocrinology 17 1880-1892. (Pubitemid 37072302)
3. Bertolino P, Tong WM, Herrera PL, Casse H, Zhang CX & Wang ZQ 2003b Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Research 63 4836-4841. (Pubitemid 37022614)
4. Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, Magnuson MA, Kay GF & Hayward NK 2004 Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Molecular and Cellular Biology 24 3125-3131. (Pubitemid 38452058)
5. Calender A, Giraud S, Cougard P, Chanson P, Lenoir G, Murat A, Hamon P & Proye C 1995 Multiple endocrine neoplasia type 1 in France: clinical and genetic studies. Journal of Internal Medicine 238 263-268.
6. Capen CC, Gröne A, Bucci TJ & Rosol TJ 1996 Changes in structure and function of the parathyroid gland. In Pathobiology of the Aging Mouse, pp 109-123. Eds U Mohru, DL Dungworth, CC Capen, WW Carlton, JP Sundberg & JM Ward. Washington DC: International Life Sciences Institute Press.
7. Chandrasekharappa SC & Teh BT 2003 Functional studies of the MEN1 gene. Journal of Internal Medicine 253 606-615.
8. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA et al. 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404-407.
9. Chang W, Tu C, Chen TH, Bikle D & Shoback D 2008 The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Science Signaling 1 ra1.
10. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ et al. 2001 A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. PNAS 98 1118-1123. (Pubitemid 32121196)
11. Crabtree JS, Scacheri PC, Ward JM, McNally SR, Swain GP, Montagna C, Hager JH, Hanahan D, Edlund H, Magnuson MA et al. 2003 Of mice and MEN1: insulinomas in a conditional mouse knockout. Molecular and Cellular Biology 23 6075-6085.
12. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ et al. 2009 Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism 94 340-350.
13. Edwards CRW & Stowasser M 2006 Primary mineralocorticoid excess syndromes. In Endocrinology, edn 5, pp 2461-2490. Eds LJ DeGroot & JL Jameson. Philadelphia: Elsevier Saunders.
14. Gibril F, Schumann M, Pace A & Jensen RT 2004 Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine 83 43-83. (Pubitemid 38124855)
15. Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K & Skogseid B 1999 Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism 84 2712-2717. (Pubitemid 30641998)
16. Helle KB, Corti A, Metz-Boutigue MH & Tota B 2007 The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cellular and Molecular Life Sciences 64 2863-2886. (Pubitemid 351152248)
17. Hough TA, Nolan PM, Tsipouri V, Toye AA, Gray IC, Goldsworthy M, Moir L, Cox RD, Clements S, Glenister PH et al. 2002 Novel phenotypes identified by plasma biochemical screening in the mouse. Mammalian Genome 13 595-602.
18. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 8 685-690. (Pubitemid 27372168)
19. Khodaei-O'Brien S, Zablewska B, Fromaget M, Bylund L, Weber G & Gaudray P 2000 Heterogeneity at the 5′-end of MEN1 transcripts. Biochemical and Biophysical Research Communications 276 508-514.
20. Larsson C, Skogseid B, Oberg K, Nakamura Y & Nordenskjold M 1988 Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332 85-87. (Pubitemid 18083554)
21. Lemos MC & Thakker RV 2008 Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Human Mutation 29 22-32.
22. Lemos MC, Harding B & Thakker RV 2007 Genetic background influences expression of multiple endocrine neoplasia type 1 (MEN1) mutation, implicating a role for genetic modifiers. Endocrine Abstracts 13 P19.
23. Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O'Connor S, Ward JM, Emmert-Buck MR, Remaley A et al. 2003 Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Research 63 8022-8028. (Pubitemid 37466741)
24. Lloyd RV, Iacangelo A, Eiden LE, Cano M, Jin L & Grimes M 1989 Chromogranin A and B messenger ribonucleic acids in pituitary and other normal and neoplastic human endocrine tissues. Laboratory Investigation 60 548-556. (Pubitemid 19141804)
25. Loffler KA, Biondi CA, Gartside M, Waring P, Stark M, Serewko-Auret MM, Muller HK, Hayward NK & Kay GF 2007 Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. International Journal of Cancer 120 259-267. (Pubitemid 44956834)
26. Lubensky IA, Debelenko LV, Zhuang Z, Emmert-Buck MR, Dong Q, Chandrasekharappa S, Guru SC, Manickam P, Olufemi SE, Marx SJ et al. 1996 Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Research 56 5272-5278. (Pubitemid 26383047)
27. Malisch JL, Kelly SA, Bhanvadia A, Blank KM, Marsik RL, Platzer EG & Garland T 2009 Lines of mice with chronically elevated baseline corticosterone levels are more susceptible to a parasitic nematode infection. Zoology 112 316-324.
28. Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Reviews. Cancer 5 367-375. (Pubitemid 40637828)
29. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS & Liotta LA 1998 Multiple endocrine neoplasia type 1: clinical and genetic topics. Annals of Internal Medicine 129 484-494. (Pubitemid 28428085)
30. Moller LN, Stidsen CE, Hartmann B & Holst JJ 2003 Somatostatin receptors. Biochimica et Biophysica Acta 1616 1-84.
31. Nesbit MA, Bowl MR, Harding B, Ali A, Ayala A, Crowe C, Dobbie A, Hampson G, Holdaway I, Levine MA et al. 2004 Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. Journal of Biological Chemistry 279 22624-22634. (Pubitemid 38679463)
32. Nyska A & Maronpot RR 1999 Pathology of the Mouse. Vienna, IL, USA: Cache River Press.
33. Pannett AA & Thakker RV 2001 Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. Journal of Clinical Endocrinology and Metabolism 86 4371-4374.
34. Scacheri PC, Crabtree JS, Novotny EA, Garrett-Beal L, Chen A, Edgemon KA, Marx SJ, Spiegel AM, Chandrasekharappa SC & Collins FS 2001 Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 30 259-263. (Pubitemid 32816509)
35. Thakker RV 2006 Multiple endocrine neoplasia type 1. In Endocrinology, edn 5, pp 3509-3531. Eds LJ DeGroot & JL Jameson. Philadelphia: Elsevier Saunders.
36. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, Besser GM & O'Riordan JL 1989 Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. New England Journal of Medicine 321 218-224. (Pubitemid 19187162)
37. The European Consortium on MEN1 1997 Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Human Molecular Genetics 6 1177-1183. (Pubitemid 27308405)
38. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S et al. 1996 Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quarterly Journal of Medicine 89 653-669.
39. Turner HE, Harris AL, Melmed S & Wass JA 2003 Angiogenesis in endocrine tumors. Endocrine Reviews 24 600-632.
40. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A 2002 Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 87 457-465. (Pubitemid 34158204)
41. Vierimaa O, Ebeling TM, Kytola S, Bloigu R, Eloranta E, Salmi J, Korpi-Hyovalti E, Niskanen L, Orvola A, Elovaara E et al. 2007 Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation. European Journal of Endocrinology 157 285-294. (Pubitemid 47603532)